Press release
Polycystic Kidney Disease Pipeline Insights 2024: Therapies, Clinical Trials, and Market Trends | Otsuka Pharma, Sanofi S.A, Reata Pharma, Galapagos N.V, Janssen Pharma, Regulus Therapeutics
The Polycystic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Polycystic Kidney Disease Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Polycystic Kidney Disease Market.
Some of the key takeaways from the Polycystic Kidney Disease Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Polycystic Kidney Disease treatment therapies with a considerable amount of success over the years.
*
Polycystic Kidney Disease companies working in the treatment market are Hannover Medical School, Otsuka Pharmaceutical, Rege Nephro Co., Ltd., Otsuka Pharmaceutical, and others, are developing therapies for the Polycystic Kidney Disease treatment
*
Emerging Polycystic Kidney Disease therapies in the different phases of clinical trials are- Empagliflozin, Tolvaptan (OPC-41061), Tamibarotene, Tolvaptan Suspension, and others are expected to have a significant impact on the Polycystic Kidney Disease market in the coming years.
*
In January 2024, Regulus Therapeutics has completed patient enrolment for the third cohort in its Phase Ib multiple-ascending dose (MAD) study of RGLS8429, a potential treatment for ADPKD. RGLS8429 aims to inhibit miR-17 and specifically target the kidneys. The Phase Ib MAD study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RGLS8429 in adults with ADPKD.
*
In November 2023, PYC Therapeutics has announced the results of a study using human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The study demonstrated that PYC-003, an investigational drug candidate developed by PYC to target the root cause of the disease, is effective. These 3D patient-derived cyst models are considered the 'gold standard' pre-clinical assay for evaluating drug candidates for this condition.
Polycystic Kidney Disease Overview
Polycystic Kidney Disease (PKD) is a genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. These cysts can enlarge the kidneys and interfere with their ability to function properly.
Get a Free Sample PDF Report to know more about Polycystic Kidney Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/polycystic-kidney-disease-pipeline-insight [https://www.delveinsight.com/report-store/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Polycystic Kidney Disease Drugs Under Different Phases of Clinical Development Include:
*
Empagliflozin: Hannover Medical School
*
Tolvaptan (OPC-41061): Otsuka Pharmaceutical
*
Tamibarotene: Rege Nephro Co., Ltd.
*
Tolvaptan Suspension: Otsuka Pharmaceutical
Polycystic Kidney Disease Route of Administration
Polycystic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Polycystic Kidney Disease Molecule Type
Polycystic Kidney Disease Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Polycystic Kidney Disease Pipeline Therapeutics Assessment
*
Polycystic Kidney Disease Assessment by Product Type
*
Polycystic Kidney Disease By Stage and Product Type
*
Polycystic Kidney Disease Assessment by Route of Administration
*
Polycystic Kidney Disease By Stage and Route of Administration
*
Polycystic Kidney Disease Assessment by Molecule Type
*
Polycystic Kidney Disease by Stage and Molecule Type
DelveInsight's Polycystic Kidney Disease Report covers around 10+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Polycystic Kidney Disease product details are provided in the report. Download the Polycystic Kidney Disease pipeline report to learn more about the emerging Polycystic Kidney Disease therapies [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Polycystic Kidney Disease Therapeutics Market include:
Key companies developing therapies for Polycystic Kidney Disease are - Otsuka Pharmaceutical, Sanofi S.A, Reata Pharmaceuticals, Galapagos N.V, Janssen Pharmaceuticals, Regulus Therapeutics, Xortx Therapeutics, AceLink Therapeutics Inc., Pano Therapeutics, Inc., Exelixis, Inc., and others.
Polycystic Kidney Disease Pipeline Analysis:
The Polycystic Kidney Disease pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Polycystic Kidney Disease with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycystic Kidney Disease Treatment.
*
Polycystic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Polycystic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycystic Kidney Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Polycystic Kidney Disease drugs and therapies [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Polycystic Kidney Disease Pipeline Market Drivers
*
Advancements in Genetic Research, Innovative Treatment Approaches, Increased Funding and Investments, Rising Prevalence, Enhanced Diagnostic Techniques, Patient Advocacy and Awareness, are some of the important factors that are fueling the Polycystic Kidney Disease Market.
Polycystic Kidney Disease Pipeline Market Barriers
*
However, High Development Costs, Regulatory Challenges, Limited Treatment Options, Complex Disease Mechanism, Side Effects and Safety Concerns, Market Competitionand other factors are creating obstacles in the Polycystic Kidney Disease Market growth.
Scope of Polycystic Kidney Disease Pipeline Drug Insight
*
Coverage: Global
*
Key Polycystic Kidney Disease Companies: Hannover Medical School, Otsuka Pharmaceutical, Rege Nephro Co., Ltd., Otsuka Pharmaceutical, and others
*
Key Polycystic Kidney Disease Therapies: Empagliflozin, Tolvaptan (OPC-41061), Tamibarotene, Tolvaptan Suspension, and others
*
Polycystic Kidney Disease Therapeutic Assessment: Polycystic Kidney Disease current marketed and Polycystic Kidney Disease emerging therapies
*
Polycystic Kidney Disease Market Dynamics: Polycystic Kidney Disease market drivers and Polycystic Kidney Disease market barriers
Request for Sample PDF Report for Polycystic Kidney Disease Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Polycystic Kidney Disease Report Introduction
2. Polycystic Kidney Disease Executive Summary
3. Polycystic Kidney Disease Overview
4. Polycystic Kidney Disease- Analytical Perspective In-depth Commercial Assessment
5. Polycystic Kidney Disease Pipeline Therapeutics
6. Polycystic Kidney Disease Late Stage Products (Phase II/III)
7. Polycystic Kidney Disease Mid Stage Products (Phase II)
8. Polycystic Kidney Disease Early Stage Products (Phase I)
9. Polycystic Kidney Disease Preclinical Stage Products
10. Polycystic Kidney Disease Therapeutics Assessment
11. Polycystic Kidney Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Polycystic Kidney Disease Key Companies
14. Polycystic Kidney Disease Key Products
15. Polycystic Kidney Disease Unmet Needs
16 . Polycystic Kidney Disease Market Drivers and Barriers
17. Polycystic Kidney Disease Future Perspectives and Conclusion
18. Polycystic Kidney Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=polycystic-kidney-disease-pipeline-insights-2024-therapies-clinical-trials-and-market-trends-otsuka-pharma-sanofi-sa-reata-pharma-galapagos-nv-janssen-pharma-regulus-therapeutics]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polycystic Kidney Disease Pipeline Insights 2024: Therapies, Clinical Trials, and Market Trends | Otsuka Pharma, Sanofi S.A, Reata Pharma, Galapagos N.V, Janssen Pharma, Regulus Therapeutics here
News-ID: 3546950 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
